Corvay Bioproducts GmbH

Leading Technology for Specialty Polymers Building Blocks – Carbon Footprint Neutral

 

  • Founded: 18.12.2018
  • Address: Am Haupttor 1
  • Zip/Postcode: 06237
  • City: Leuna
  • Country: DE
  • Mail: albrecht.laeufer@corvay-bioproducts.com
  • Phone:
  • Contact person for business: Dr. Albrecht Läufer
  • Contact person for science: Dr. Joachim Schulze

Company summary

Corvay Bioproducts GmbH has been established at the end of 2018 and has acquired and further developed production biotechnology for a unique class of building blocks for high performance plastics, long chain aliphatic diacids, especially DDDA, dodecane dioic acid. The company will commercialize the platform by subsequent development of processes for dioc acids and license the technology packages.

Technology field

Biotransformation, production of chemicals from renewable resources, Bioeconomy, Sustainability

Technology and USP

several patents, production strains and technology protocols acquired from Verdezyne Inc., fermentation and biotransformation scale up is complete, 30cbm scale. Downstream and Purification proprietary improvements at lab scale, PCT application filed end 2019.
USP: i. feedstock is plant oil, product 100% biobased, ii. best in class DSP process iii. competitive production cost

Development until now

see technology

Capital requirements:

Corvay Bioproducts is raising 3 million Euro for the proof-of-concept in pilot scale and demon-stration at production scale of its newly designed downstream and purification technology, with subsequent establishment of a production company. Corvay Bioproducts will need one year to demonstrate commercial viability of its proprietary process and will then be able to license out this process to the production company. The company will be profitable from the second year after closing. Based on three products successfully developed and licensed out IRR will be 26%!

Founder

Albrecht Läufer

Dr. Albrecht Läufer has over 30 years of international management experience in the pharmaceutical and chemical industries. He is managing director of Corvay GmbH and Corvay Specialty Chemicals GmbH in Hannover. Since 2017he is co-investor and managing director of BluCon Biotech GmbH, Cologne. In 2002 he was a co-founder of Vakzine Projekt Management GmbH, which he built up and managed from 2003 to 2008. He holds a doctorate in physical chemistry from Technical University of Braunschweig